Equities research analysts expect Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) to post ($0.18) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Corbus Pharmaceuticals’ earnings. Corbus Pharmaceuticals also reported earnings per share of ($0.18) in the same quarter last year. The company is scheduled to report its next quarterly earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Corbus Pharmaceuticals will report full year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.62) to ($0.58). For the next year, analysts forecast that the firm will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.78) to ($0.69). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Corbus Pharmaceuticals.
Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 1,040.41%.
A number of equities analysts have weighed in on the company. BidaskClub downgraded Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals in a research report on Friday, December 15th. Cantor Fitzgerald set a $28.00 price target on Corbus Pharmaceuticals and gave the stock an “overweight” rating in a research report on Thursday, December 14th. Finally, ValuEngine downgraded Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $25.00.
Corbus Pharmaceuticals (NASDAQ CRBP) opened at $7.00 on Friday. Corbus Pharmaceuticals has a 12-month low of $5.30 and a 12-month high of $10.50.
In other news, Director David P. Hochman bought 5,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were bought at an average price of $6.90 per share, with a total value of $34,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David P. Hochman bought 10,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was purchased at an average cost of $7.08 per share, for a total transaction of $70,800.00. Following the transaction, the director now directly owns 459,500 shares of the company’s stock, valued at approximately $3,253,260. The disclosure for this purchase can be found here. Insiders bought 25,336 shares of company stock worth $175,632 in the last ninety days. 11.90% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of CRBP. State Street Corp grew its position in shares of Corbus Pharmaceuticals by 2,998.2% in the second quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock valued at $3,708,000 after purchasing an additional 569,662 shares during the last quarter. Northern Trust Corp grew its position in shares of Corbus Pharmaceuticals by 814.3% in the second quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock valued at $3,039,000 after purchasing an additional 429,584 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Corbus Pharmaceuticals by 24.5% in the second quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock valued at $9,850,000 after purchasing an additional 307,979 shares during the last quarter. Artal Group S.A. acquired a new stake in Corbus Pharmaceuticals during the second quarter worth approximately $1,575,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in Corbus Pharmaceuticals during the second quarter worth approximately $760,000. 27.84% of the stock is currently owned by institutional investors.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.